1
|
Kruithof PD, de Beer YM, Gulikers JL, Stolk LML, Hendriks LEL, Croes S, van Geel RMJM. Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs. J Chromatogr B Analyt Technol Biomed Life Sci 2023; 1231:123918. [PMID: 37979367 DOI: 10.1016/j.jchromb.2023.123918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 10/11/2023] [Accepted: 10/27/2023] [Indexed: 11/20/2023]
Abstract
Recently, two small molecular inhibitors (SMIs) -adagrasib and sotorasib- have been introduced for targeting Kirsten rat sarcoma (KRAS) p.G12C mutations in patients with non-small cell lung cancer (NSCLC). In order to support pharmacokinetic research as well as clinical decision making, we developed and validated a simple and accurate liquid chromatography-tandem mass spectrometry method for the multiplexed quantification of adagrasib and sotorasib. This assay was co-validated with the quantification for brigatinib, lorlatinib, pralsetinib and selpercatinib. Methanol was used for single-step protein precipitation. Chromatographic separation was performed using an Acquity® HSS C18 UPLC column, with an elution gradient of ammonium formate 0.1 % v/v in water and acetonitrile. In K2-EDTA plasma, adagrasib was found to be stable for at least seven days at room temperature and 4 °C, and at least 3 months at -80 °C. Sotorasib was found to be stable for at least three days at room temperature, seven days at 4 °C and at least 3 months at -80 °C. The method was validated over a linear range of 80-4000 ng/mL for adagrasib and 25-2500 ng/mL for sotorasib. The assay is therefore well-equipped for determining plasma concentrations in clinical practice.
Collapse
Affiliation(s)
- Paul D Kruithof
- Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, MD, Maastricht, the Netherlands
| | - Yvo M de Beer
- Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands
| | - Judith L Gulikers
- Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, MD, Maastricht, the Netherlands
| | - Leo M L Stolk
- Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands
| | - Lizza E L Hendriks
- Department of Pulmonary Diseases, GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands
| | - Sander Croes
- Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, MD, Maastricht, the Netherlands
| | - Robin M J M van Geel
- Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, AZ, Maastricht, the Netherlands; CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, MD, Maastricht, the Netherlands.
| |
Collapse
|
2
|
Al-Dahmani ZM, Li X, Wiggenhauser LM, Ott H, Kruithof PD, Lunev S, A Batista F, Luo Y, Dolga AM, Morton NM, Groves MR, Kroll J, van Goor H. Thiosulfate sulfurtransferase prevents hyperglycemic damage to the zebrafish pronephros in an experimental model for diabetes. Sci Rep 2022; 12:12077. [PMID: 35840638 PMCID: PMC9287301 DOI: 10.1038/s41598-022-16320-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 07/08/2022] [Indexed: 12/18/2022] Open
Abstract
Thiosulfate sulfurtransferase (TST, EC 2.8.1.1), also known as Rhodanese, was initially discovered as a cyanide detoxification enzyme. However, it was recently also found to be a genetic predictor of resistance to obesity-related type 2 diabetes. Diabetes type 2 is characterized by progressive loss of adequate β-cell insulin secretion and onset of insulin resistance with increased insulin demand, which contributes to the development of hyperglycemia. Diabetic complications have been replicated in adult hyperglycemic zebrafish, including retinopathy, nephropathy, impaired wound healing, metabolic memory, and sensory axonal degeneration. Pancreatic and duodenal homeobox 1 (Pdx1) is a key component in pancreas development and mature beta cell function and survival. Pdx1 knockdown or knockout in zebrafish induces hyperglycemia and is accompanied by organ alterations similar to clinical diabetic retinopathy and diabetic nephropathy. Here we show that pdx1-knockdown zebrafish embryos and larvae survived after incubation with thiosulfate and no obvious morphological alterations were observed. Importantly, incubation with hTST and thiosulfate rescued the hyperglycemic phenotype in pdx1-knockdown zebrafish pronephros. Activation of the mitochondrial TST pathway might be a promising option for therapeutic intervention in diabetes and its organ complications.
Collapse
Affiliation(s)
- Zayana M Al-Dahmani
- Department of Pharmacy and Drug Design, University of Groningen, Groningen, The Netherlands
| | - Xiaogang Li
- Department of Vascular Biology and Tumor Angiogenesis, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, 68167, Mannheim, Germany
| | - Lucas M Wiggenhauser
- Department of Vascular Biology and Tumor Angiogenesis, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, 68167, Mannheim, Germany.,Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands
| | - Hannes Ott
- Department of Vascular Biology and Tumor Angiogenesis, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, 68167, Mannheim, Germany
| | - Paul D Kruithof
- Department of Pharmacy and Drug Design, University of Groningen, Groningen, The Netherlands
| | - Sergey Lunev
- Department of Pharmacy and Drug Design, University of Groningen, Groningen, The Netherlands
| | - Fernando A Batista
- Department of Pharmacy and Drug Design, University of Groningen, Groningen, The Netherlands
| | - Yang Luo
- Department of Pharmacy, Molecular Pharmacology, University of Groningen, Groningen, The Netherlands
| | - Amalia M Dolga
- Department of Pharmacy, Molecular Pharmacology, University of Groningen, Groningen, The Netherlands
| | - Nicholas M Morton
- Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK
| | - Matthew R Groves
- Department of Pharmacy and Drug Design, University of Groningen, Groningen, The Netherlands. .,XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, 9700 AD, Groningen, The Netherlands.
| | - Jens Kroll
- Department of Vascular Biology and Tumor Angiogenesis, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, 68167, Mannheim, Germany
| | - Harry van Goor
- Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands. .,Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, 9700 RB, Groningen, The Netherlands.
| |
Collapse
|
3
|
Kruithof PD, Lunev S, Aguilar Lozano SP, de Assis Batista F, Al-Dahmani ZM, Joles JA, Dolga AM, Groves MR, van Goor H. Unraveling the role of thiosulfate sulfurtransferase in metabolic diseases. Biochim Biophys Acta Mol Basis Dis 2020; 1866:165716. [PMID: 32061776 DOI: 10.1016/j.bbadis.2020.165716] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Revised: 01/10/2020] [Accepted: 01/30/2020] [Indexed: 02/08/2023]
Abstract
Thiosulfate sulfurtransferase (TST, EC 2.8.1.1), also known as Rhodanese, is a mitochondrial enzyme which catalyzes the transfer of sulfur in several molecular pathways. After its initial identification as a cyanide detoxification enzyme, it was found that its functions also include sulfur metabolism, modification of iron‑sulfur clusters and the reduction of antioxidants glutathione and thioredoxin. TST deficiency was shown to be strongly related to the pathophysiology of metabolic diseases including diabetes and obesity. This review summarizes research related to the enzymatic properties and functions of TST, to then explore the association between the effects of TST on mitochondria and development of diseases such as diabetes and obesity.
Collapse
Affiliation(s)
- Paul D Kruithof
- Univeristy of Groningen, Department of Pharmacy and Drug Design, the Netherlands
| | - Sergey Lunev
- Univeristy of Groningen, Department of Pharmacy and Drug Design, the Netherlands
| | | | | | - Zayana M Al-Dahmani
- Univeristy of Groningen, Department of Pharmacy and Drug Design, the Netherlands
| | - Jaap A Joles
- University Medical Center Utrecht, Department of Nephrology and Hypertension, the Netherlands
| | - Amalia M Dolga
- University of Groningen, Department of Pharmacy, Molecular Pharmacology, the Netherlands
| | - Matthew R Groves
- Univeristy of Groningen, Department of Pharmacy and Drug Design, the Netherlands
| | - Harry van Goor
- University Medical Center Groningen, Department of Pathology and Medical Biology the Netherlands.
| |
Collapse
|